Bexarotene
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | TARGRETIN | — | 2015-07-29 | fda.gov ↗ |
| Approved | EU (EMA) | Targretin | — | 2001-03-29 | europa.eu ↗ |
| Approved | US (FDA) | TARGRETIN | — | 1999-12-29 | fda.gov ↗ |
Trials 38 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01782742 Comparator | Feb 2013 → Aug 2014 | Alzheimer disease | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00178841 Background | Jun 2005 → Mar 2007 | Sezary syndrome, mycosis fungoides | Vanderbilt University | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01578499 Comparator | Jun 2012 → May 2016 | mycosis fungoides, primary cutaneous anaplastic large cell lymphoma | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00535574 Comparator | Nov 2008 → Dec 2010 | schizophrenia | Beersheva Mental Health Center | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05106192 Background | Apr 2022 → Jun 2025 | anaplastic large cell lymphoma, follicular lymphoma, lymphomatoid papulosis, mycosis fungoides | Case Comprehensive Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 46 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bexarotene | “Targretin® (bexarotene) Gel 1% a synthetic vitamin A compound that is approved for the topical treatment and oral treatment of cutaneous T cell lymphoma (CTCL).” NCT00063076 ↗42“Azacitidine Bexarotene Bortezomib” NCT02551718 ↗ |
| Known as | Bexaroteno | ChEMBL registry synonym — accepted as the source's own label CHEMBL1023 ↗ |
| Known as | LG-100069 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1023 ↗ |
| Known as | LGD1069 | “In this proposed study, we aim to investigate the effects of Bexarotene (Targretin; LGD1069; 4-\[1-{5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl} ethenyl\] benzoic...” NCT00141947 ↗3“OBJECTIVES: I. Compare the efficacy of oral bexarotene (LGD1069) at two different dose levels in patients with advanced breast cancer.” NCT00003752 ↗ “bexarotene (Targretin; LGD1069;” NCT00534898 ↗ “Bexarotene (Targretin LGD1069)” NCT00535574 ↗ |
| Known as | NSC-747528 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1023 ↗ |
| Known as | Targretin | “In this proposed study, we aim to investigate the effects of Bexarotene (Targretin; LGD1069; 4-\[1-{5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl} ethenyl\] benzoic...” NCT00141947 ↗11“This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in...” NCT00050973 ↗ “Investigator-Initiated, Double Blind, Vehicle-Controlled, Bilateral Comparison Trial of Bexarotene (Targretin) Gel 1% vs. Vehicle Gel in Combination With Narrow Band UVB...” NCT00151008 ↗ “The purpose of this study is to learn about the effects of two new anticancer drugs, erlotinib (Tarceva) and bexarotene (Targretin), when treating patients with advanced lung cancer.” NCT00125359 ↗ “bexarotene (Targretin capsules, Ligand Pharmaceuticals, San Diego, Calif) alone and then with the addition of interferon alfa-2b (Intron-A, Schering-Plough, Kenilworth, NJ).” PMID 17366595 ↗ May 2007 “Bexarotene (Targretin) is a synthetic retinoid mainly used for treatment of patients suffer from oncological or dermatological diseases.” NCT00535574 ↗ “combined bexarotene (Targretin(®) ) and PUVA vs. PUVA alone in patients with stage IB and IIA mycosis fungoides (MF).” PMID 22924950 ↗ Sep 2012 “A Multicenter Phase II Evaluation of Targretin (Bexarotene) Capsules in Patients With Advanced Breast Cancer” NCT00003752 ↗ “Targretin capsules (bexarotene)” NCT00050960 ↗ “bexarotene (Targretin; LGD1069;” NCT00534898 ↗ “Targretin® (bexarotene)” NCT00255801 ↗ “Bexarotene (Targretin®)” NCT01116622 ↗ |
| Known as | Targretine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1023 ↗ |
| Action | Deplete | “can cause the death of T-cells” NCT00063076 ↗ |
| Modality | Small molecule | “This drug is a retinoid.” NCT00055991 ↗ |
| Route | Oral | “All patients receive oral bexarotene once daily.” NCT00003752 ↗ |